First-of-its-Kind vaccine aims to stop rare liver cancer from coming back
NCT ID NCT06789198
Summary
This early-stage trial is testing a new personalized vaccine for patients with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC). The vaccine is designed to teach the patient's own immune system to recognize and attack any remaining cancer cells after initial treatment, with the goal of preventing the cancer from returning. The study will enroll about 20 patients who have already achieved remission through surgery or other therapies to see if the vaccine is safe and can trigger a helpful immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Tuebingen
RECRUITINGTübingen, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsklinikum Tübingen, Kinderheilkunde I
NOT_YET_RECRUITINGTübingen, 72076, Germany
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.